Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1704602 | 0.92 | TSHR (0.66) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL8424369 | 0.92 | TSHR (0.66) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL10348567 | 0.90 | TSHR (0.60) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL9806862 | 0.88 | TSHR (0.75) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL28905711 | 0.88 | TSHR (0.74) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL427500 | 0.87 | TSHR (0.58) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL29139797 | 0.86 | TSHR (0.77) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL9505548 | 0.86 | TSHR (0.77) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL10939056 | 0.86 | TSHR (0.77) | TSHRDNM1THRBALDH1A1POLB | |
| SCHEMBL9667032 | 0.86 | TSHR (0.63) | TSHRDNM1THRBALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118139858-A | Pyrazin-3 (2H) -one derivatives | 吉利德科学公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230257386-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-08-17 | — | — | US | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11535622-B2 | Pyrrolo[1,2-b] pyridazine derivatives | GILEAD SCIENCES, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210214363-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | GILEAD SCIENCES, INC. | 2021-07-15 | — | — | US | disclosed |
| US-20030064999-A1 | A2B adenosine receptor antagonists | PALLE VENKATA (US) | 2003-04-03 | — | — | US | disclosed |
| US-6528511-B2 | E.g., ranolazine | CV THERAPEUTICS, INC. | 2003-03-04 | — | — | US | disclosed |
| US-6525057-B2 | In binder film | CV THERAPEUTICS, INC. | 2003-02-25 | — | — | US | disclosed |
| US-6503911-B2 | Administering a sustained release pharmaceutical dosage form including ranolazine for therapy of cardiovascular disease selected from arrhythmias, variant and exercise-induced angina, and myocardial infarction | CV THERAPEUTICS, INC. | 2003-01-07 | — | — | US | disclosed |
| US-6479496-B1 | TREATING A HUMAN PATIENT SUFFERING FROM VARIANT AND EXERCISE-INDUCED ANGINA BY ADMINISTERING A SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORM INCLUDING AT LEAST 50% BY WEIGHT RANOLAZINE IN NO MORE THAN TWO TABLETS PER DOSE | CV THERAPEUTICS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020128266-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| US-20020090396-A1 | Sustained release ranolazine formulations | CV THERAPEUTICS, INC. | 2002-07-11 | — | — | US | disclosed |
| US-6369062-B1 | TABLET WITH PH DEPENDENT METHACRYLIC ACID COPOLYMER BINDER, HYDROXYPROPYL METHYLCELLULOSE, MICROCRYSTALLINE CELLULOSE, SODIUM HYDROXIDE, AND MAGNESIUM STERATE | CV THERAPEUTICS, INC. | 2002-04-09 | — | — | US | disclosed |
| US-20010047000-A1 | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | GILEAD SCIENCES, INC. | 2001-11-29 | — | — | US | disclosed |
| US-6303607-B1 | ADMINISTERING SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORM INCLUDING RANOLAZINE, PH-DEPENDENT AND PH-INDEPENDENT BINDERS TO HUMAN SUFFERING FROM VARIANT OR EXCERCISE-INDUCED ANGINA | CV THERAPEUTICS, INC. | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214363-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | TSHR 2044/4885DNM1 275/4885THRB 1555/4885 |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | TSHR 1080/4885DNM1 3776/4885THRB 700/4885 |
| US-20030064999-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | TSHR 811/4885DNM1 3486/4885THRB 344/4885 |
| US-11572362-B2 | Pyrrolo[1,2-b]pyridazine derivatives | CYP11B2, CYP11B1, DHPS | TSHR 2596/4885DNM1 285/4885THRB 1556/4885 |
| US-11535622-B2 | Pyrrolo[1,2-b] pyridazine derivatives | CYP11B2, CYP11B1, DHPS | TSHR 2044/4885DNM1 275/4885THRB 1555/4885 |
| US-20230257386-A1 | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | CYP11B2, CYP11B1, DHPS | TSHR 2044/4885DNM1 275/4885THRB 1555/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | TSHR 2900/4885DNM1 2953/4885THRB 600/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | TSHR 2222/4885DNM1 1577/4885THRB 3327/4885 |
| US-20020128266-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | TSHR 3699/4885DNM1 866/4885THRB 1762/4885 |
| US-20010047000-A1 | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure | FABP3, COXFA4, CPT2 | TSHR 2860/4885DNM1 2438/4885THRB 2161/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | TSHR 2900/4885DNM1 2953/4885THRB 600/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | TSHR 1080/4885DNM1 3776/4885THRB 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.